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Review
Prospects for Radiopharmaceuticals
as Effective and Safe Therapeutics
in Oncology and Challenges of Tumor
Resistance to Radiotherapy
Ekaterina Nikolova1 , Dimitar Tonev1, Nikolai Zhelev2,3, and Vladimir Neychev4
Abstract
The rapid advances in nuclear medicine have resulted in significant advantages for the field of oncology. The focus is on the
application of radiopharmaceuticals as therapeuticals. In addition, the latest developments in cell biology (the understanding of the
cell structure, function, metabolism, genetics, signaling, transformation) have given a strong scientific boost to radiation oncology.
In this regard, the article discusses what is soon going to be a new jump in radiation oncology based on the already accumulated
considerable knowledge at the cellular level about the mechanisms of cell transformation and tumor progression, cell response to
radiation, cell resistance to apoptosis and radiation and cell radio-sensitivity. The mechanisms of resistance of tumor cells to
radiation and the genetically determined individual sensitivity to radiation in patients (which creates the risk of radiation-induced
acute and late side effects) are the 2 major challenges to overcome in modern nuclear medicine. The paper focuses on these
problems and makes a detailed summary of the significance of the differences in the ionizing properties of radiopharmaceuticals
and the principle of their application in radiation oncology that will shed additional light on how to make the anti-cancer
radiotherapies more efficient and safe, giving some ideas for optimizations.
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Introduction
Radiation oncology aims at selective cytotoxic effects on the
tumor cells in the patient’s body with the application of ionizing
radiation. In this regard, the cytotoxic effects of the anticancer
radiotherapy are a complex function of 3 factors—the type of the
applied therapeutic ionizing radiation; the patient’s cancer cells’
radio-resistance; and the genetically determined individual
radio-sensitivity of the cancer patient which determines each
patient’s individual tolerance to therapeutic irradiation and the
risk of acute/late side effects (Figure 1).
Despite the considerable advances the nuclear medicine has
achieved over the last decades, the latest global cancer data of
the World Health Organization reported 9.6 million cancer
deaths in 2018 against the background of 18.1 million new
cases of cancer patients registered in the same year [https://
www.who.int/cancer/PRGlobocanFinal.pdf]. It brings the need
for further optimization of the anticancer radiotherapies which
requires constant reviews of the numerous research publica-
tions in physics, radiobiology and cancer biology. This review
points out some options for optimization summarizing the
already accumulated significant scientific knowledge on: the
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nature of ionizing radiation; the ionizing effects of radiophar-
maceuticals at the cellular level and how these effects differ
depending on the nature of the radiopharmaceuticals; the
mechanisms of the radio-resistance in tumor cells, and the
genetically determined differences among individuals in regard
to their radio-sensitivity. Our final goal is to discuss the poten-
tial of ionizing radiation to provide an effective antitumor
therapy capable of defeating therapy-resistant cancer cells
based entirely on the molecular mechanisms of these processes.
Nature and Types of Ionizing Radiation
and Their Relation to the Elicited
Intracellular Ionizing Effects
The knowledge of the differences in the nature of ionizing
radiation resulting in different ionizing effects at the cellular
level and the cell’s response to radiation can be used to improve
the efficiency of anticancer radiotherapy. The cytotoxic
anti-cancer effects in radiation oncology are provoked by
radioactive isotopes of well-known chemical elements called
“radionuclides.” However, the term “radionuclides” is very
common and includes a huge variety of radionuclides with
different physical and chemical properties which reflects the
ionizing and cytotoxic effects of each radionuclide, making it
unique. The ability to predict and control the biological effects
of the radiopharmaceuticals applied in nuclear medicine is only
possible if there is an understanding of the physical and chem-
ical characteristics of each radiopharmaceutical. The good
knowledge about the nature of ionizing radiation helps in the
following directions in the therapeutic applications of radio-
nuclides, allows: to measure and control the radiation dose and
dose rate based on the half-life of the specific radionuclide (and
its daughter nuclides); to determine the ionizing strength of the
radionuclide by the number of the ionizing events caused per
unit area (the so-called Linear Energy Transfer (LET) values of
the radionuclides); to predict the predominant type of the DNA
damage that occurred—base oxidations and single
strand-brakes versus more complex double-strand brakes based
on the mass and the charge of the ionizing particles; and to
predict the specific penetration ranges of the different types of
ionizing radiation into matter (respectively into the human
body) and to calculate the diameter of the ionizing effect of
the targeted radionuclides.1-4
The possibility to determine the dose and dose rate of the
radiation of a given radionuclide has led to 3 beneficial appli-
cations of radiation in medicine: for diagnostic purposes—to
label cells; for therapeutic purposes—to induce healing
through regeneration; and for cytotoxicity—to kill cells. These
could be achieved in different ways.
At a low dose and with a targeting strategy (which in addi-
tion requires good knowledge about cell biology), suitable
radionuclides with a short half-life can be used to achieve safe
and functional cell-labeling and visualization in the multicel-
lular human body for the purpose of the nuclear diagnostic
techniques such as PET/CT, SPECT/CT, PET/MRI. The
shorter the half-life and metabolism of the radiopharmaceuti-
cal, the more suitable for diagnostic purposes. Gamma and
positron emitters with low LET values are preferable because
of their weaker ionizing properties in comparison to alpha
radiopharmaceuticals.
At low doses and at low rates, radiation may provide med-
icine with another benefit—to induce cell repair and tissue/
organ regeneration through the so-called mild stress activated
protection system in each living cell.5-7 Billions of years ago
life on our planet appeared and existed in an environment with
several orders of magnitude higher levels of natural radiation.8
Thus, the single cells and the cells of multicellular organisms
have developed their complex intrinsic antioxidant defense
which performs 2 functions—first, to eliminate the free radi-
cals generated by the radiolysis of the cellular water after irra-
diation (known as “indirect” oxidizing effects of radiation on
cellular biomolecules—proteins, lipids, nucleic acids) and sec-
ond, to detect and repair the consequences of the “indirect” and
also of the “direct” ionizing effects of radiation on the cellular
DNA molecules after it deposits its energy directly to eject
electrons from these important macromolecules of the cells.
In this regard, the cells within the multicellular human body
have developed a very complex and multileveled defense sys-
tem. It includes intracellular antioxidant enzymes (catalase,
superoxide dismutase, peroxidase, peroxiredoxins),6,9 glu-
tathione,10 free radicals scavenging pigments—intrinsic to the
cells (melanin)11 or food-supplied pigments (phytochem-
icals),12 vitamins (A, C, E),13,14 hormones (melatonin).15
Cellular lipids and microRNAs are also an important part of
the different mechanisms working together to deactivate
directly the dangerous free radicals or to protect the cell by
activating a strong anti-apoptotic and/or pro-survival intracel-
lular signaling pathways.16-20 In addition, the cellular antiox-
idant defense system includes DNA damage detecting and
repairing enzymes (over 130 DNA repairing enzymes operate
in each human cell in a highly organized manner).21,22 Another
level of the cellular antioxidant defense is represented by
the mechanism of the “protective apoptosis” which cleans the
irreversibly damaged cells out of the multicellular organism,
thus protecting the whole organism against diseases (the
Figure 1. Set of factors determining the optimal results of a cancer
patient’s radiotherapy.
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p53-dependent and p-53-independent apoptosis, 2 mechanisms
that are obviously lost in every radio-resistant cancer cell).23,24
This ability of the cells to protect themselves against radiation
creates the so-called “Hormesis Theory” in biophysics and
allows the use of ionizing radiation at low doses and low rates
to achieve regeneration of tissues with chronic inflammation
(atopic dermatitis, asthma, rheumatoid arthritis) or for curing
people with cancer.25-27
At high doses and high dose rates, ionizing radiation
becomes cytotoxic and this is used in radiation oncology to
target and kill tumor cells. Since in oncology the dose and dose
rate can not be increased unrestrictedly in achieving an effi-
cient cytotoxic antitumor effect due to the radiation tolerance
of the normal organs and tissues surrounding the tumor,28 other
characteristics of the radiopharmaceuticals are to be considered
for their efficient cytotoxicity. Research experiments from the
past years demonstrate that the higher the LET of the radio-
nuclide, the bigger the complexity and the number of the DNA
double-strand breaks versus the DNA single-strand breaks.1,4
The bigger the complexity of the DNA damage, the higher the
effectiveness against even the strongest anti-apoptotic mechan-
isms in all radio-resistant tumor cells as such cytotoxicity is
able to cause death in tumor cells through necrosis rather than
apoptosis.29 In biophysics the high LET values are demon-
strated by a-particle-emitting radionuclides followed by beta
and gamma radionuclides. How does this change the biological
effectiveness of radionuclides to such an extent that research
and clinical data are replete with examples of beta- and
gamma-resistant tumor cells even at high radiation doses but
at the same time there are no examples of alpha radiation-
resistant tumor cells? Since the specific physical characteristics
of the different types of ionizing radiation are critical for the
final results of the application of radiopharmaceuticals in radia-
tion oncology, a brief discussion in the following 3 paragraphs
is needed on why the different nature of radiation elicits
differences in the number and complexity of the DNA strand
breaks, the extent of the observed gammaH2AX-foci forma-
tion, the induction of cell cycle checkpoint and DNA repair
instead of cell apoptosis or necrosis.
According to its nature ionizing radiation is an emission (or
transmission) of energy that comes from the radioactive decay
of an unstable radioisotope (a radionuclide) and in some cases
this energy is in the form of highly energetic electromagnetic
waves (photons), in other cases it is highly energetic subatomic
particles (protons, electrons, bare helium atoms) that are able to
eject electrons when hitting an atom of a molecule causing
ionization of the molecule (which is the principle of radiation
cytotoxicity in the context of radiation application as an
anti-tumor treatment).
Depending on the nature and size of the ionizing particles,
the ionizing effects and the penetrating power of the different
types of ionizing radiation differ. The largest and heaviest
alpha particles, compare to gamma and beta ones, penetrate
the least (mm into a matter such as the human body) and since
they are doubly charged they are relatively slow and show
bigger ionizing effects (the strongest cytotoxic effects) into
matter than the photons which have zero electrical charge and
zero mass. Having no mass or charge, gamma radiation can
travel much farther through air or matter than alpha or beta
radiation and thus has greater penetrating ability (measured
in cm into the human body). Beta particles in contrast to
photons possess a charge and a mass, but in comparison to
alpha particles they have a single charge (positive or negative)
and a 8000 times smaller size. Thus, beta particles interact less
strongly with matter than alpha particles, traversing through the
human body with penetration ranges of mm to a few cm. It
means that in regard to its ionizing properties beta radiation
ranks between gamma and alpha radiation.
It also gives us an explanation of why the different nature of
ionizing radiation results in a different outcome at the cellular
level which reflects the strength of the cytotoxic effects of the
various radiopharmaceuticals at the same doses and dose rates
applied for treatment in radiation oncology. The successful
results in radiation oncology depend on the right choice of
a radionuclide which in turns depends on the final goal—
diagnostics or treatment.30 While the medical diagnostic tech-
niques using radionuclides in the form of tracers excelled and
achieved great precision due to the rapid advances in cell biol-
ogy, immunology, physics, pharmacochemistry, medicine, and
engineering with the introduction of PET/CT- and SPECT/
CT-scanners for positron- and gamma-emitting radiopharma-
ceuticals, there is still a long way to go until the full potential of
radionuclides as successful anti-cancer therapeutics is reached.
This is especially true for alpha radionuclides which until
recently have been considered of no medical use because of
their strong ionizing properties.27,30,31
The next part of the review considers already available
scientific evidence that with the right scientific strategy
alpha-radionuclides can not only find their medical application
but also save lives where the weaker ionizing photon and beta
radiations fail in the treatment of apoptosis-resistant tumors and
even speed up the tumor growth with their weaker ionizing
properties.27,28,32
Tumor Cells Radioresistance as a Function of
Complex Factors—a Large Number of
Hidden Pro-Survivalmechanisms in Tumor
Cells, Limited Diagnostic Capabilities in
Clinics and Wrong Approaches in the
Application of Antitumor Strategies
Cancer has become a scourge for modern society since the
factors provoking it have multiplied in everyday life—stress,
poor diet, pollution, artificial toxic substances in food, the
aging population of the developed countries, some inherited
genetic factors, etc. The lack of response to the existing chemo-
and radio-therapies in almost 50% of cancer patients forces
scientists to continue studying the resistance mechanisms of
tumor cells.18,19,20,28,30,33-38 With no intention to be exhaustive,
Figure 2 summarizes schematically the diversity of these
mechanisms. The need to search for stronger cytotoxic
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therapies that could be targeted and are capable of defeating
this cancer cells’ resistance, whatever its molecular mechan-
isms are, is becoming more and more apparent. The extended
cancer research has revealed that cancer is a disease connected
to normal cell transformation due to randomly acquired one or
more mutations resulting in a dramatic change of the otherwise
well-controlled intracellular signaling pathways for cell
growth, capable to reverse cell differentiation, to suppress
apoptosis and, unfortunately, to assure long-term survival
under cytotoxic conditions exceeding the survival rate of nor-
mal cells. The more research and clinical data accumulate, the
more obvious it becomes how easily some tumor cells are able
to overcome the cytotoxic effects of photon- and beta-emitters
which are the predominating radio-therapeutics in the current
clinical practice because of their weaker ionizing properties in
comparison to alpha radiopharmaceuticals.30,31 For example,
MOLT-4 human T lymphoblasts, isolated from a patient with
an acute lymphoblastic leukemia and irradiated with a 100 Gy
proton beam, 24 h after the irradiation show no signs of induced
apoptosis. Other cells famous for their resistance to treatment
such as Head and Neck Squamous Cell Carcinoma (HNSCC)
cells, also survive after repeated exposure to X-rays ionizing
radiation with a total dose of 100 Gy and researchers are
amazed to observe that the ionizing-resistant cells retained
their radiation resistance even after 3 years of in vitro passa-
ging.32,37 These doses of beta and photon radiation exceed the
tolerance of normal tissues and organs to radiation and are still
not effective against tumor cells.28
The advance in radiation biology today, especially after the
discovery of radiation biodosimetry, has revealed that the prob-
lem with cancer cell resistance to radiotherapy is multifaceted.
On the one hand, the photons and beta particles cannot induce
efficient mitochondrial and/or DNA damage capable of trigger-
ing cell apoptosis, mitotic catastrophe or necrosis.1,29,32,39 On
the other hand, the mechanism of the cytotoxic effect of photon
and beta radiation (which includes activation of apoptosis as a
secondary effect of the radiation-induced free radicals genera-
tion)4,39,40 may be counteracted by many intracellular
mechanisms in apoptosis-resistant tumor cells (Figure 2).
These mechanisms for counteraction include—efficient neutra-
lization of the generated free radicals41-43; activation of pro-
longed check points for DNA-strand breaks repair36;
constitutive activation of strong pro-survival and
anti-apoptotic signaling37,44 or impaired activation of
pro-apoptotic signaling.45 The complexity of the pro-survival
mechanisms of cancer cells under cytotoxic conditions grows
with the observation that these mechanisms involve not only
protein signaling but also lipid-18 and miRNA-signaling.20,46
The current chemotherapies usually target deregulated protein
signaling in tumor cells such as growth factor receptors or
another downstream of the receptor oncogenes in an attempt
to sensitize them to the concomitant radiotherapy28,33 but at the
same time the lipid- and miRNA-signaling that function in
parallel to protein signaling to support the radio-resistance of
tumor cells is not considered during therapy. Undoubtedly, this
will complicate significantly and increase the cost of the pre-
ceding diagnostic process, which will have to identify the lipid-
and miRNA-signaling involved in tumor cells’ resistance to
therapy in parallel to protein tumor markers.
Another factor that can contribute to the complexity of cancer
cells resistance to therapy and compromise the efficiency of
anti-cancer radiotherapy is cancer cells polyploidy.47,48 Accord-
ing to the cited studies, for example, a significant percentage of all
breast and pancreatic cancers are polyploid. The polyploidy is a
predictor of cancer recurrence or death, the authors say. Cancer
cell polyploidy can be considered a predictor of radiotherapy
resistance too. More chromosomes means more copies of genes
coding for enzymes of the antioxidant defense system and more
genes for DNA repair proteins which will weaken the cytotoxic
effects of the radiation in the irradiated tumor cells. However,
when determining the efficient therapeutic radiation dose soft-
ware such as Geant4 misses to consider in its calculating algo-
rithms that polyploid cancer cells survive better than diploid cells
after irradiation under the attack of the same number of
radiation-generated genotoxic free radicals.4 The analogy of
polyploid tumor cells with the radioresistance record-holder—the
Figure 2. Complexity of the pro-survival mechanisms of cancer cells under cytotoxic conditions. The mechanisms of cytotoxicity of anti-tumor
radiotherapy and chemotherapy are different. Accordingly, the mechanisms used by tumor cells to counteract this toxicity also differ markedly.
The specific cellular molecular mechanisms underlying the radio- and chemo-therapy resistance are presented in blue and red respectively.
Where radiotherapy and chemotherapy are intended to achieve genotoxicity through oxidation and DNA strand breaks, tumor cells use the
same counteracting mechanisms such as activation of strong anti-apoptotic signaling pathways as well as activation of DNA-repairing pathways
(the cellular mechanisms indicated in purple).
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bacterium Deinococcus radiodurans, which is distinguished by
the large number of copies of its genome, is self-imposed.49
The diet of cancer patients during radiotherapy can also
affect the efficiency of the radiotherapy in many ways which
calls for some discussion on this point. The fact that radiation
can cause cancer50 and at the same time can cure cancer
requires extremely detailed knowledge of the mechanisms of
radiation action at the cellular level and the mechanisms by
which cells counteract these effects. Radiation is part of our
daily life since the emergence of life on earth8 and the living
cells have developed mechanisms to sense it51,52 and to protect
themselves from it.53 Our food is important part of these
mechanisms. A diet rich in fruits, vegetables and herbs is che-
mopreventive (protective against oxidative damage) for
healthy individuals due to the potent antioxidant activity of its
vitamins (carotenoids, tocopherols, ascorbic acid), minerals
(Cr, Mn, Se or Zn), phytochemical compounds (polyphenols,
alkaloids, saponins, glycosides, resins, oleoresins, sesquiter-
pene, and lactones) which leads to 1) reduced oxidative damage
in macromolecules such as DNA and lipids by scavenging the
reactive oxygen, nitrogen species and chelating redox-active
transition metal ions, 2) inhibition of both the apoptotic process
induced by ROS and the redox-sensitive transcription factors;
3) inhibition of “pro-oxidant” enzymes, such as inducible nitric
oxide synthase, lipoxygenases, cyclooxygenases and xanthine
oxidase; 4) induction of antioxidant enzymes, such as
glutathione-S-transferases and superoxide dismutases 5) posi-
tive modulation of radiation-induced DNA damage
repair.12,13,19,38,54,55 For healthy individuals or individuals
undergoing radio-diagnostic procedures this food antioxidant
activity is beneficial but during anti-cancer photon and beta
radiotherapy it can attenuate the cytotoxic effects of the irra-
diation on tumor cells. In this regard, despite being debatable
and largely rejected in some standard oncology practices, the
therapeutic effects of short-term fasting during anticancer ther-
apy should be discussed.56-59 Clinical studies confirmed that
when conducted exclusively under medical supervision and
after careful assessment of the patient’s condition
(early-stage cancer with no signs of severe weight loss, dia-
betes, sarcopenia, cachexia or eating disorders), short-term
water-only fasting just before and after radiotherapy could
enhance the cytotoxic effects on the tumor cells at many lev-
els.56 Such an additional metabolic therapy contributes to the
increased stress on oncogene-driven tumor cells during chemo/
radio therapy—it reduces the amount of their main source of
energy and building blocks for growth, DNA repair and poli-
feration, gradually weakening all anti-apoptotic signaling path-
ways maintained by nutrition. Fasting is used as a strategy to
lower the serum levels of glucose, insulin and insulin-like
growth factor 1 (IGF-1) just before, during and after therapy
which is critical for the tumor cells survival as glucose fuels
tumor cells with energy in the form of ATP through both aero-
bic or anaerobic (hypoxic tumor growth) glycolysis. Insulin
and IGF-1, in their turn, activate the cellular pro-proliferative
Ras/MAPK signaling pathway and the strong anti-apoptotic
PI3K/AKT pathway.
When antitumor radiotherapy is not successful, the reasons
usually are sought in the failure of the DNA damage-induced
p-53-mediated pro-apoptotic signaling but the lack of activation
of the cytoplasmic mitochondrial apoptotic pathway is not dis-
cussed. Fasting is the simplest and non-toxic strategy to sensitize
tumor cells to radiation-induced apoptosis through switching off
the “insulin!Akt!Hexokinase II!mitochondrial protec-
tion!cell survival pathway” in them, a signaling already
observed to be protective against oxidative injury in adenocar-
cinomic human alveolar basal epithelial cells A549 for exam-
ple.60 The active AKT is cental in mitochondrial protection and
intracellular antiapoptotic mechanisms, it inhibits also the
Ca2þ-induced pathway for apoptosis, transcriptionally
up-regulates the anti-apoptotic Bcl, and inhibits through phos-
phorylation the pro-apoptotic Bax and Bad. Any chemical inhi-
bition of Akt protein as an antitumor chemotherapy can be risky
since this protein is critical for the viability of the cardiac muscle
cells (the so called chemotherapy-induced cardiotoxicity).60
Fasting can weaken naturally Akt-signaling in oncogene-
driven tumor cells facilitating their apoptosis when in healthy
cells oncogenes switch off and only re-investment of energy in
maintenance and repair is induced. This well-observed distinct
response of healthy versus tumor cells to fasting is called
“differential stress resistance” (DSR). It protects all healthy
cells from the detrimental effects of chemo- and radio-therapy
observed in the form of severe acute and late side effects at a
body level (fatigue, nausea, vomiting, cachexia, inflammation,
secondary cancer). More importantly, the DSR phenomenon
promotes efficient anti-tumor immunity in the human body
through mechanisms discussed by Groot et al. in their review.56
Instead, the standard medical protocols in the clinics include
immunosuppressive corticosteroids to suppress the side effects
of chemo- and radio-therapy. Fasting can also facilitate the
p53-induced apoptosis through Akt-inhibition or even compen-
sate for the lack of p53-mediated Akt-inhibition in tumor cells.61
In the context of anti-tumor radiotherapy, fasting is benefi-
cial in yet another way—it deprives temporarily tumor cells of
fats. Fats are a great source of energy (fat provides 9 calories
per gram whereas carbohydrates provide 4 kcal per gram and
protein—4 calories per gram) but at the same time, dietary fats
supply tumor cells with important structural materials for
building their membrane structures necessary for growth and
proliferation, contributing to faster recovery of tumor cells
after irradiation. Last but not least—fat metabolism supports
the synthesis of cofactors such as lipoic acid for enzyme func-
tion and one of the strongest known antioxidants inside the
cells.16 As Ralph et al. point out in their review62 cancer cells
show significantly increased levels and activity of the enzymes
involved in metabolizing fatty acids both for synthesis and
degradation of these energy sources.
Currently, the cytotoxic oxidative effects on tumor cells
pursued in clinics by photon and beta antitumor radiotherapy
are largely failed and we argue that this is partially a result of
lack of participation in the treatment team of specialists in
tumor signaling and metabolism (extremely extensive areas
in tumor biology) and a certified dietitian. This type of
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professional intervention is critical because even the positive
effects of fasting during antitumor radiotherapy may be ham-
pered by factors as obesity due to the excess fat stored in
adipose tissue,63 and nutrient deprivation–induced autophagy
in tumor cells conferring their survival through the signaling
pathway: nutrient deficiency!energy shortage!increased
AMP/ATP ratio!AMPK activation!mTORC1 inhibi-
tion!autophagy induction for energy production.29,44,64-67 Not
only nutrient deprivation but also activational mutation in
autophagy related proteins or radiation in itself through
LKB1-phosphorylation and activation is able to induce the
same signaling pathway for autophagy which should be con-
sidered a possible mechanism of tumor cells survival during
radiotherapy.52,64 Despite all this knowledge, it is not yet a
concomitant part of the clinical practices of antitumor photon
and beta therapies and as such it can not help in increasing the
effectiveness of these therapies.
One of the many reasons for the lack of induced apoptosis in
tumor cells after radiotherapy is the defective signaling pro-
teins controlling positively the activation of the protease and
nuclease enzymes performing the process of programmed cell
death. An inactive p53-protein is often observed in cancer
patients not responding to therapy and strategies for restoring
its function have been suggested as anti-cancer therapies.68
However, p53 is just a single part of a very complicated nuclear
signaling network of more than 130 DNA-checking and repair-
ing proteins which work in synchrony to keep the integrity of
the cellular DNA, to check for DNA base oxidations, to detect
single- and double-strand brakes, to accomplish the right
mechanism for DNA repair and, in case of unrepairable DNA
damage, to signal for activation of the process of protective
apoptosis in the cells with defective DNA which is critical to
the health of multicellular organisms. The above said should be
considered when planning a chemotherapy accompanying the
radiotherapy with inhibition of the DNA repairing proteins—a
strategy already applied in clinics28 or often discussed in sci-
entific reviews,69 since in this way pro-apoptotic signaling can
be inhibited in tumor cells, for example PARP-mediated or
DNA-PK-/ceramide-mediated apoptosis induction.40,70-74
Since gamma- and beta-emitting radionuclides are applied
in the clinic as antitumor therapeutics to induce apoptosis in
tumor cells as a secondary effect of irradiation and free radicals
generation,29,32 all possible reasons for the lack of success of
these therapies have to be discussed regardless of how numer-
ous they might be. The radiotherapies that generate free radi-
cals and DNA-base oxidations in tumor cells but are not
sufficient to induce apoptosis can be dangerous rather than
helpful for the cancer patients. The reason is that if tumor cells
possess active mechanisms to efficiently decrease the cytotoxi-
city of free radicals, then at moderate concentations free radi-
cals have proven able to exert physiological control on
important cellular functions, for example, to stimulate cell pro-
liferation and motility,75,76 to induce prolonged cell cycle
checkpoint for DNA repair,36,44 to generate more gene muta-
tions that lead to more mutated proteins not responding to the
chemical inhibitors of the ongoing chemotherapy, the so-called
“acquired chemotherapy resistance.”77,78
In almost 50% of the cancer patients treated with the current
photon or beta radiation techniques in the clinic the tumor cells
do not respond in the expected way with induced apoptosis
although these cells possess all the physiological features of
cells that should be very sensitive to radiation. They have a
faster metabolism than normal cells for energy production
which charges them with more reactive oxygen species—
superoxide radicals during the process of ATP synthesis and
hydrogen peroxide from the fatty acids oxidation.62 A tumor
cell contains more water than a normal cell79 which is supposed
to make it more vulnerable to radiation. Tumor cells proliferate
abnormally80 which should make them more sensitive to cyto-
toxic effects as it happens with all normal quickly dividing
stem cells in the human body or with embryonic cells after
irradiation.81,82 In addition, during radiotherapy the radiation
targeting the tumor cells generates free radicals in these cells
not only by water molecules radiolysis but also through direct
activation of derivative systems such as NADPH oxidase and
inducible NO synthase (iNOS).83 Instead of becoming apopto-
tic under all these conditions the therapy resistant tumor cells
survive and even happen to accelerate their growth after irra-
diation.27,28,30 It is obvious that the current clinical practice
needs stronger cytotoxic anti-tumor therapy capable to defeat
the complex anti-apoptotic strength of the tumor cells resistant
to therapy. Nuclear physics and nuclear medicine can offer
such a therapy through the common introduction of
alpha-radiopharmaceuticals as antitumor therapeutics in the
clinical practice.
The way of alpha-radionuclides to the clinic has already
been paved by convincing clinical data confirming the risk of
the application of an internal targeted beta-radiotherapeutical
(177Lutetium-PSMA-617 ligand) in the treatment of a patient
with an advanced apoptosis-resistant metastatic prostate cancer
resulting in increased values of the tumor marker after the
beta-radiotherapy and, on the other hand, the life-saving
results after the application of an internal targeted alpha-
radiopharmaceutical (225Actinium-PSMA-617ligand) in the
same patient.27 The efficient anti-tumor cytotoxicity and the
safe range of penetration of the alpha-emitter for the patient
with tumor cells resistant to beta-radiation and with red marrow
metastasis are obvious. As a well-designed targeted immu-
notherapy and with proper chelators assuring selective target-
ing to cancer cells and strong binding with a quick release out
of the body of the radionuclide respectively, the targeted
alpha-radiotherapy is the long-waited solution for patients with
difficult-to-treat tumor cells.27 The reported lack of serious
acute side effects during alpha radiotherapy with 225Actinium
is also very encouraging.
The diversity in the chemical properties of the different
existing alpha-emitters creates different treatment options for
cancer patients, for example by an internal non-targeted inha-
lation therapy with the noble gas 222Radon (222Rn). The radio-
nuclide 222Rn combines the properties of a chemically inert
noble gas and alpha-emitter with a relatively short half-life
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(3,8d); its pharmacokinetics shows that when it is inhaled or
absorbed through the skin, radon is released out of the human
body in 50-60 minutes, a period much shorter than its half--
life.84 The radon inertness and its quick release out of the body
explain why radon as internal nontargeted radiotherapy is capa-
ble of causing just mild injuries in the human body but enough
to induce regeneration without any serious harm to the organ-
ism. Such an anti-cancer therapy continues a bit longer, from
8 to 12 months, but has proven effective in curing 2 advanced
breast cancer patients with numerous metastasis including
brain metastasis proven by 3 years of complete remission.27
Inter-Individual Differences in Human
Radiosensitivity
Like all other medicines, radiopharmaceuticals should also be
provided with detailed instructions about any contraindica-
tions. Biodosimetry based on gammaH2AX foci assay has to
become an integral part of all radiation procedures in the clinic
both diagnostic and therapeutic.
In vitro biodosimetric tests with peripheral blood cells
(lymphocytes) of healthy volunteers have provided data that
improved the understanding about human sensitivity to geno-
toxicity which may assure the safe application of all radiophar-
maceuticals in the clinic. Two risky groups of people have been
identified with regard to the biodosimetric technique. The first
group of people is characterized by the observation that upon
genotoxic treatment with the same dose as other people a
greater initial number of DNA gmmaH2AX foci are formed
in the nuclei of their cells and this phenomenon is not related to
gender or age.85 It has been suggested that the observed higher
initial number of DNA breaks can be associated with the
unlocking of more acute adverse reactions (neutropenia, febrile
neutropenia, thrombocytopenia, gastric or duodenal ulcer,
ascites) during chemo- and radio-therapy with these patients.
Short-term therapeutic fasting 24-48 hours before therapy
could accompany chemo- and radio-therapy in such cases as
it has been proven clinically to help reduce the side effects of
cytotoxic therapies.56,64 It should also be checked whether
radon therapy for such patients is a more appropriate option
as it induces slow regeneration during a longer period of treat-
ment with low doses and low dose rates instead of using strong
cytotoxic high radiation doses and high dose rates.26,27
As already mentioned, a second group of radiosensitive
people has also been identified by means of biodosimetry. In
this group of people the radiation-induced DNA foci demon-
strate significantly delayed kinetics in their repair. Since DNA
foci have strict kinetics of formation and repair,86,87 any delay
in their repair time indicates some DNA repair enzyme defi-
ciency which leads to a greater residual number of unrepaired
DNA foci 24 hours after irradiation.88,89 For these people any
form of radiation is contraindicative and carcinogenics90 and
other diagnostic and anti-tumor treatment options must be
considered.
The study of the molecular mechanisms of the genetically-
determined radiosensitivity in people must continue with the
techniques available today in modern radiobiology and biodo-
simetry.91 The identification of radiosensitive people is of fun-
damental importance because if they stay unidentified and
when admitted as patients in radiation oncology clinics, there
will always be a compromise on the positive results from the
application of radiation and radiopharmaceuticals as a thera-
peutic treatment.
Conclusions and Recommendations
The already accumulated large amount of scientific data makes
the introduction of functional tests for radiosensitivity in the
clinical practice mandatory.92 All cancer patients who show
biomarkers of radiosensitivity should be considered individu-
ally in the clinics. In these cases, a different planning approach
must be employed toward the intended radio-therapies and
their application as a diagnostic or therapeutic method will
hugely depend on the extent of the patient’s individual radio-
sensitivity. In all other cancer cases, the chosen clinical
approach will be guided and determined by the characteristics
of the tumor cells and their potential to undergo or resist apop-
tosis upon treatment with the weaker ionizing gamma/beta
radiation.28,29,30,32 Alpha-radiotherapies must be considered
for all patients with apoptosis-resistant tumors.27 The
life-saving nature of the alpha radiotherapy for patients with
difficult-to-treat cancer brings the fastly emerging need for the
creation of a sufficient number of production centers. The pro-
vision of the necessary radionuclides for future scientific and
clinical research will assure the continuous optimization of the
alpha therapy.
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54. Cabrera C, Artacho R, Giménez R. Beneficial effects of green
tea-a review. J Am Coll Nutr. 2006;25(2):79-99.
55. Gao K, Henning SM, Niu Y, et al. The citrus flavonoid naringenin
stimulates DNA repair in prostate cancer cells. J Nutr Biochem.
2006;17(2):89-95.
56. de Groot S, Pijl H, van der Hoeven JJM, Kroep JR. Effects of
short-term fasting on cancer treatment. J Exp Clin Cancer Res.
2019;38(1):209. doi:10.1186/s13046-019-1189-9
57. Klement RJ. Fasting, fats, and physics: combining ketogenic and
radiation therapy against cancer. Complement Med Res. 2018;
25(2):102-113. doi:10.1159/000484045
58. Zhang J, Deng Y, Khoo BL. Fasting to enhance cancer treatment
in models: the next steps. J Biomed Sci. 2020;27(1):58.
59. Seyfried T. Cancer as a Metabolic Disease: On the Origin,
Management and Prevention of Cancer. John Wiley & Sons, Inc;
2016.
60. Miyamoto S, Murphy AN, Brown JH. Akt mediated mitochon-
drial protection in the heart: metabolic and survival pathways to
the rescue. J Bioenerg Biomembr. 2009; 41(2): 169-180.
61. Kim C W, Lu J N, Go SI, et al. p53 restoration can overcome
cisplatin resistance through inhibition of Akt as well as induction
of Bax. Int J Oncol. 2013;43(5):1495-1502.
62. Ralph SJ, Rodrı́guez-Enrı́quez S, Neuzil J, Moreno-Sánchez R.
Bioenergetic pathways in tumor mitochondria as targets for can-
cer therapy and the importance of the ROS-induced apoptotic
trigger. Mol Aspects Med. 2009;31(1):29-59.
63. Stone TW, McPherson M, Darlingtond LG. Obesity and cancer:
existing and new hypotheses for a causal connection. EBioMedi-
cine. 2018;30:14-28.
64. Antunes F, Erustes AG, Costa AJ, et al. Autophagy and intermit-
tent fasting: the connection for cancer therapy? Clinics. 2018;
73(suppl 1):e814. doi:10.6061/clinics/2018/e814 s
65. Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-
activated protein kinase (AMPK) and cancer: many faces of a
metabolic regulator. Cancer Lett. 2015;356(2 pt A):165-170.
doi:10.1016/j.canlet.2014.01.018
66. Fulda S. Autophagy in cancer therapy. Front Oncol. 2017;7;128.
doi:10.3389/fonc.2017.00128.
67. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy
promotes tumor cell survival and restricts necrosis, inflammation,
and tumorigenesis. Cancer Cell. 2006;10(1):51-64.
68. Lane DP, Cheok CF, Lain S p53-based cancer therapy. Cold
Spring Harb Perspect Biol. 2010;2(9):a001222. doi:10.1101/
cshperspect.a001222
69. Zucca E, Crespan E, Bertoletti F, Kissova M, Maga G. Two Birds
With a Stone: Molecular Cancer Therapy Targeting Signal Trans-
duction and DNA Repair Pathways. Bonavida B. Resistance to
Targeted Anti-Cancer Therapeutics. Springer ScienceþBusiness
Media New York; 2013:163-187.
70. Boulares AH, Yakovlev AG, Ivanova V, et al. Role of poly(ADP-
ribose) polymerase (PARP) cleavage in apoptosis. Caspase
3-resistant PARP mutant increases rates of apoptosis in trans-
fected cells. J Biol Chem. 1999;274(33):22932-22940.
71. Bharti A, Kraeft S, Gounder M, et al. Inactivation of
DNA-dependent protein kinase by protein kinase Cd: implica-
tions for apoptosis. Mol Cell Biol. 1998;18(11):6719-6728.
72. Chakravarthy BR, Walker T, Rasquinha I, Hill IE, MacManus JP.
Activation of DNA-dependent protein kinase may play a role in
Nikolova et al 9
apoptosis of human neuroblastoma cells. J Neurochem. 1999;
72(3):933-942.
73. Lucero H, Gae D, Taccioli GE. Novel localization of the DNA-PK
complex in lipid rafts: a putative role in the signal transduction
pathway of the ionizing radiation response. J Biol Chem. 2003;
278(24):22136-22143.
74. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radia-
tion acts on cellular membranes to generate ceramide and initiate
apoptosis. J Exp Med. 1994;180(2):525-535.
75. Peus D, Meves A, Vasa RA, Beyerle A, O’Brien T, Pittelkow MR.
H2O2 is required for UVB-induced EGF receptor and down-
stream signaling pathway activation. Free Radic Biol Med.
1999;27(11-12):1197-1202.
76. Galli A, Svegliati-Baroni G, Ceni E, et al. Oxidative stress stimulates
proliferation and invasiveness of hepatic stellate cells via a MMP2-
mediated mechanism. Hepatology. 2005;41(5):1074-1084.
77. Olinski R, Jaruga P, Zastawny T. Chapter 29 Estimation of free
radical induced DNA base damages in cancerous- and HIV infected
patients and in healthy subjects. Advances in DNA Damage and
Repair. Oxygen Radical Effects, Cellular Protection, and Biological
Consequences. In: Dizdaroglu M, Karakaya A, eds. NATO ASI
Series. Springer ScienceþBusiness Media, 1999:353-369.
78. Freeman A, Morrison D. Mechanisms and Potential Therapies for
Acquired Resistance to Inhibitors Targeting the Raf or Mek kinases
in Cancer. Bonavida b. Resistance to Targeted Anti-Cancer Thera-
peutics. Springer ScienceþBusiness Media New York; 2013:47-69.
79. Ross KFA, Gordon RE. Water in malignant tissue, measured by
cell refractometry and nuclear magnetic resonance. J Microsc.
1982; 128(1):7-21.
80. Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained
proliferation in cancer: mechanisms and novel therapeutic targets.
Semin Cancer Biol. 2015;35Suppl(Suppl):S25-S54. doi:10.1016/
j.semcancer.2015.02.006
81. Acharya MM, Lan ML, Kan VH, et al. Consequences of ionizing
radiation-induced damage in human neural stem cells. Free Radic
Biol Med. 2010;49(12):1846-1855.
82. Sokolov MV, Neumann RD. Human embryonic stem cell
responses to ionizing radiation exposures: current state of
knowledge and future challenges. Stem Cells Int. 2012;2012:
579104. doi:10.1155/2012/579104
83. Reisz J A, Bansal N, Qian J, Zhao W, Furdui C M. Effects of
ionizing radiation on biological molecules-mechanisms of dam-
age and emerging methods of detection. Antioxid Redox Signal.
2014;21(2):260-292.
84. Becker K. One century of radon therapy. 2004. Inl J Low Radiat.
2004;1(3):334-357.
85. Ismail IH, Wadhra TM, Hammarsten O. An optimized method for
detecting gamma-H2AX in blood cells reveals a significant inter-
individual variation in the gamma-H2AX response among
humans. Nucleic Acids Res. 2007;35(5):e36. doi:10.1093/nar/
gkl1169
86. Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K,
Takeda S. The controlling role of ATM in homologous recombi-
national repair of DNA damage. EMBO J. 2000;194(4):463-471.
87. Torudd J, Protopopova M, Sarimov R, et al. Dose–response for
radiation-induced apoptosis, residual 53BP1 foci and DNA-loop
relaxation in human lymphocytes. Int J Radiat Biol. 2005;81(2):
125-138.
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